Avalo Therapeutics (NASDAQ:AVTX) Trading Down 6.9% – Time to Sell?

Avalo Therapeutics, Inc. (NASDAQ:AVTX)’s share price fell 6.9% on Monday . The stock traded as low as $20.12 and last traded at $20.0860. 1,193,236 shares were traded during mid-day trading, an increase of 22% from the average session volume of 978,365 shares. The stock had previously closed at $21.57.

Analysts Set New Price Targets

Several brokerages have recently weighed in on AVTX. Citigroup restated an “outperform” rating on shares of Avalo Therapeutics in a report on Wednesday, May 6th. Citizens Jmp upped their price objective on Avalo Therapeutics from $52.00 to $62.00 and gave the company a “market outperform” rating in a report on Wednesday, May 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Wednesday, April 8th. Wall Street Zen upgraded Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, March 29th. Finally, Guggenheim began coverage on Avalo Therapeutics in a report on Monday, February 2nd. They issued a “buy” rating and a $50.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Avalo Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $49.63.

Avalo Therapeutics Price Performance

The firm has a market capitalization of $582.20 million, a PE ratio of -3.46 and a beta of 0.78. The firm has a fifty day moving average price of $15.84 and a 200 day moving average price of $16.44.

Avalo Therapeutics (NASDAQ:AVTX) last announced its earnings results on Wednesday, May 13th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.02. On average, sell-side analysts expect that Avalo Therapeutics, Inc. will post -3.1 EPS for the current year.

Insider Buying and Selling

In related news, insider Mittie Doyle sold 3,970 shares of the stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $18.01, for a total value of $71,499.70. Following the completion of the sale, the insider directly owned 3,622 shares of the company’s stock, valued at approximately $65,232.22. This represents a 52.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Ryan Sullivan sold 8,457 shares of the stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $13.23, for a total value of $111,886.11. Following the completion of the sale, the chief financial officer directly owned 423 shares of the company’s stock, valued at approximately $5,596.29. This represents a 95.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 138,078 shares of company stock valued at $2,501,346. Corporate insiders own 4.46% of the company’s stock.

Institutional Investors Weigh In On Avalo Therapeutics

Hedge funds have recently bought and sold shares of the business. BIT Capital GmbH purchased a new stake in Avalo Therapeutics in the 3rd quarter worth about $25,000. PFS Partners LLC lifted its stake in Avalo Therapeutics by 100.0% in the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after acquiring an additional 1,000 shares in the last quarter. Boothbay Fund Management LLC purchased a new stake in Avalo Therapeutics in the 2nd quarter worth about $56,000. Dimensional Fund Advisors LP purchased a new stake in Avalo Therapeutics in the 3rd quarter worth about $143,000. Finally, AlphaCentric Advisors LLC purchased a new stake in Avalo Therapeutics in the 1st quarter worth about $174,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.